Pancreatic Islet Organoid – Glucose Sensitivity

  • Pancreatic Islet Organoid – Glucose Sensitivity

Pancreatic Islet Organoid – Glucose Sensitivity

Diabetes and metabolic disorders remain among the most pressing global health challenges, yet preclinical models often fail to fully capture the biology of human insulin-producing β-cells. At Greenstone Biosciences, we address this gap by generating pancreatic islet organoids composed exclusively of functional islet cells from human induced pluripotent stem cells (iPSCs).

These islet organoids faithfully replicate the cellular composition, signaling pathways, and glucose responsiveness of the human endocrine pancreas. By focusing on insulin-secreting β-cells alongside supporting islet cell types, our system provides a highly physiologically relevant platform for studying glucose metabolism and insulin regulation in vitro.

Key Capabilities

Glucose Responsiveness

Evaluate dynamic insulin secretion in response to varying glucose concentrations, modeling real human physiology.

β-Cell Function & Health

Assess β-cell viability, stress responses, and functional capacity over time.

Mechanistic Insights

Investigate pathways underlying β-cell dysfunction, insulin resistance, and progression of diabetes.

Drug Candidate Evaluation

Test novel compounds that enhance β-cell function, improve insulin secretion, or modulate glucose metabolism.

Why It Matters

Most available diabetes models rely on animal systems or immortalized cell lines, which often lack the fidelity to human β-cell biology. By recreating functional islet cells from iPSCs, our platform provides:

  • Human-relevant insights into the mechanisms of diabetes and metabolic disorders.
  • Predictive evaluation of candidate therapeutics in a system that mimics human glucose metabolism.
  • Reduced reliance on animal models, accelerating translational research.

Applications in Discovery & Development

The Pancreatic Islet Organoid platform supports both basic research—to uncover the cellular and molecular drivers of diabetes—and translational applications, where drug candidates can be screened and validated in a physiologically relevant context. This enables smarter, data-driven therapeutic development for type 1 diabetes, type 2 diabetes, and other metabolic diseases.

Advancing Precision Medicine in Metabolism

By leveraging iPSC technology to recreate human islet biology in vitro, Greenstone Biosciences provides a powerful bridge between laboratory research and clinical application. Our platform empowers scientists and drug developers to advance the next generation of metabolic therapeutics—faster, safer, and with greater confidence in human relevance.

Enquire Now